公开(公告)号：US20240424060A1

公开(公告)日：2024-12-26

申请号：US18763519

申请日：2024-07-03

Applicant: DOMPE' FARMACEUTICI SPA

Inventor： Andrea ARAMINI ,  Pier Giorgio AMENDOLA ,  Anna SIRICO ,  Gaetano D'ANNIBALLE ,  Franca CATTANI ,  Marcello ALLEGRETTI ,  Flavio MANTELLI

IPC: A61K38/18 ,  A61P27/02

Abstract: The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.

公开(公告)号：US20240091311A1

公开(公告)日：2024-03-21

申请号：US18275849

申请日：2022-02-04

Applicant: DOMPE' FARMACEUTICI SPA

Inventor： Andrea ARAMINI ,  Pier Giorgio AMENDOLA ,  Anna SIRICO ,  Gaetano D'ANNIBALLE ,  Franca CATTANI ,  Marcello ALLEGRETTI ,  Flavio MANTELLI

IPC: A61K38/18 ,  A61P27/02

CPC classification number: A61K38/185 ,  A61P27/02

Abstract: The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.

公开(公告)号：US20230141355A1

公开(公告)日：2023-05-11

申请号：US17914529

申请日：2021-03-24

Applicant: Dompe' Farmaceutici SPA

Inventor： Marcello ALLEGRETTI ,  Flavio MANTELLI ,  Lorenzo PIEMONTI

IPC: A61K31/18 ,  A61K31/675 ,  A61K31/737 ,  A61K31/573 ,  A61K31/496 ,  A61K31/431 ,  A61K38/20 ,  A61K31/635 ,  A61K31/167 ,  A61K31/616 ,  A61K31/415 ,  A61K31/7052 ,  A61K31/546 ,  A61K31/135 ,  A61P31/14

CPC classification number: A61K31/18 ,  A61K31/675 ,  A61K31/737 ,  A61K31/573 ,  A61K31/496 ,  A61K31/431 ,  A61K38/2006 ,  A61K31/635 ,  A61K31/167 ,  A61K31/616 ,  A61K31/415 ,  A61K31/7052 ,  A61K31/546 ,  A61K31/135 ,  A61P31/14

Abstract: The present invention relates to CXCL8 inhibitors for use in the treatment of COVID-19 patients with pneumonia.